JP Morgan Chase
RARE icon

JP Morgan Chase’s Ultragenyx Pharmaceutical RARE Stock Holding History

JP Morgan Chase’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.75M Sell
245,928
-3,728,102
-94% -$84M ﹤0.01% 3358
2025
Q4 		$91.4M Sell
3,974,030
-37,399
-0.9% -$1.23M 0.01% 984
2025
Q3 		$121M Buy
4,011,429
+750,561
+23% +$22.5M 0.01% 899
2025
Q2 		$119M Buy
3,260,868
+2,951,397
+954% +$106M 0.01% 862
2025
Q1 		$11.2M Buy
309,471
+103,684
+50% +$4.31M ﹤0.01% 2435
2024
Q4 		$8.66M Sell
205,787
-7,423
-3% -$368K ﹤0.01% 2831
2024
Q3 		$11.8M Sell
213,210
-7,815
-4% -$398K ﹤0.01% 2463
2024
Q2 		$9.08M Sell
221,025
-31,135
-12% -$1.33M ﹤0.01% 2541
2024
Q1 		$11.8M Sell
252,160
-25,782
-9% -$1.22M ﹤0.01% 2339
2023
Q4 		$13.3M Buy
277,942
+2,351
+0.9% +$91.1K ﹤0.01% 2193
2023
Q3 		$9.82M Sell
275,591
-37,554
-12% -$1.49M ﹤0.01% 2253
2023
Q2 		$14.4M Buy
313,145
+24,077
+8% +$1.12M ﹤0.01% 1974
2023
Q1 		$11.6M Sell
289,068
-6,087
-2% -$261K ﹤0.01% 2155
2022
Q4 		$13.7M Sell
295,155
-17,616
-6% -$693K ﹤0.01% 1984
2022
Q3 		$13M Buy
312,771
+17,814
+6% +$915K ﹤0.01% 1952
2022
Q2 		$17.6M Sell
294,957
-6,186
-2% -$381K ﹤0.01% 1713
2022
Q1 		$21.9M Sell
301,143
-20,411
-6% -$1.42M ﹤0.01% 1695
2021
Q4 		$27M Buy
321,554
+11,303
+4% +$920K ﹤0.01% 1571
2021
Q3 		$28M Sell
310,251
-40,668
-12% -$3.68M ﹤0.01% 1520
2021
Q2 		$33.5M Buy
350,919
+44,440
+15% +$4.63M ﹤0.01% 1435
2021
Q1 		$34.9M Buy
306,479
+75,049
+32% +$10.2M ﹤0.01% 1346
2020
Q4 		$32M Buy
231,430
+45,456
+24% +$5.39M ﹤0.01% 1303
2020
Q3 		$15.8M Buy
185,974
+36,867
+25% +$3.06M ﹤0.01% 1667
2020
Q2 		$11.7M Buy
149,107
+37,397
+33% +$2.48M ﹤0.01% 1776
2020
Q1 		$4.96M Buy
111,710
+55,186
+98% +$2.87M ﹤0.01% 2268
2019
Q4 		$2.41M Buy
56,524
+35,368
+167% +$1.46M ﹤0.01% 3248
2019
Q3 		$906K Buy
21,156
+3,107
+17% +$169K ﹤0.01% 3895
2019
Q2 		$1.12M Sell
18,049
-1,227
-6% -$78.1K ﹤0.01% 3790
2019
Q1 		$1.34M Buy
19,276
+5,645
+41% +$323K ﹤0.01% 3614
2018
Q4 		$593K Buy
13,631
+594
+5% +$32.5K ﹤0.01% 4042
2018
Q3 		$995K Sell
13,037
-3,688
-22% -$300K ﹤0.01% 3923
2018
Q2 		$1.28M Sell
16,725
-4,372
-21% -$282K ﹤0.01% 3679
2018
Q1 		$1.08M Sell
21,097
-570
-3% -$28.7K ﹤0.01% 3637
2017
Q4 		$1M Sell
21,667
-169,537
-89% -$8.31M ﹤0.01% 3731
2017
Q3 		$10.3M Sell
191,204
-3,536
-2% -$210K ﹤0.01% 1955
2017
Q2 		$12.1M Sell
194,740
-48,866
-20% -$2.94M ﹤0.01% 1830
2017
Q1 		$16.5M Sell
243,606
-12,039
-5% -$918K ﹤0.01% 1589
2016
Q4 		$18M Sell
255,645
-25,904
-9% -$1.84M ﹤0.01% 1524
2016
Q3 		$20M Buy
281,549
+18,212
+7% +$1.16M ﹤0.01% 1371
2016
Q2 		$12.9M Buy
263,337
+5,806
+2% +$376K ﹤0.01% 1691
2016
Q1 		$16.3M Buy
257,531
+14,863
+6% +$973K ﹤0.01% 1470
2015
Q4 		$27.2M Buy
242,668
+60,442
+33% +$6.04M 0.01% 1132
2015
Q3 		$17.6M Buy
182,226
+46,328
+34% +$5.3M ﹤0.01% 1353
2015
Q2 		$13.9M Sell
135,898
-70,532
-34% -$5.48M ﹤0.01% 1665
2015
Q1 		$12.8M Buy
206,430
+5,137
+3% +$285K ﹤0.01% 1735
2014
Q4 		$8.83M Buy
201,293
+5,793
+3% +$265K ﹤0.01% 2040
2014
Q3 		$11.1M Sell
195,500
-2,575
-1% -$130K ﹤0.01% 1844
2014
Q2 		$8.89M Buy
198,075
+16,515
+9% +$680K ﹤0.01% 1804
2014
Q1 		$8.88M Buy
+181,560
New +$9.35M ﹤0.01% 1782

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase's RARE Position: Q1 2026 in Review

JP Morgan Chase reduced its Ultragenyx Pharmaceutical (RARE) stake by 94% in Q1 2026, selling an estimated $84M and leaving 245,928 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

JP Morgan Chase first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $121M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • JP Morgan Chase held 245,928 shares of Ultragenyx Pharmaceutical worth $4.75M as of Q1 2026.
  • JP Morgan Chase sold 3,728,102 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $84M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3358 holding.
  • JP Morgan Chase first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • JP Morgan Chase's Ultragenyx Pharmaceutical position peaked at $121M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.